Enliven Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-32.49Mn |
Net Profit Margins | -Inf% |
Enliven Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Enliven Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Enliven Therapeutics, Inc. Common Stock’s net profit fell -28.22% since last year same period to $-32.49Mn in the Q2 2026. On a quarterly growth basis, Enliven Therapeutics, Inc. Common Stock has generated -37.49% fall in its net profits since last 3-months.
Enliven Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Enliven Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Current Year | -0.38 |
Enliven Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.38 - a 7.32% jump from last quarter’s estimates.
Enliven Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.38.
Key Ratios
Earning Per Share (EPS) | -0.49 |
Enliven Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 0% since last year same period to -0.49 in the Q2 2026. This indicates that the Enliven Therapeutics, Inc. Common Stock has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-07 | -0.41 | -0.38 | 7.32% |
2026-08-05 | -0.38 | -0.49 | -28.95% |
